OBJECTIVETo review the relation between dietary omega-3 polyunsaturated fatty acids (omega-3 PUFA) and non-communicable diseases.

METHODData were collected from scientific journals and conference publications, MEDLINE (1979 - 2002) and current content which included 68 prospective, cross-sectional, case control and dietary-intervention studies. Scientific paper selections were based on the association between omega-3 PUFA and non-communicable diseases.

RESULTSomega-3 PUFA has beneficial effects on increasing heart rate variability, decreasing the risk of stroke, reducing both systolic and diastolic blood pressure, insulin resistance and glucose metabolism. Long chain omega-3 PUFA has anti-cancer and anti-inflammatory activities. omega-3 PUFA has also been reported to have a beneficial effect on attention-deficit/hyperactivity disorder and schizophrenia, and may be effective in managing depression in adults.

CONCLUSIONSResults from epidemiological and dietary intervention studies have shown that omega-3 PUFA represent powerfully a class of bioactive compounds and that dietary intake of omega-3 PUFA plays a critical role in human health in relation to non-communicable diseases.

Diabetes Mellitus ; therapy ; Fatty Acids, Omega-3 ; administration & dosage ; pharmacology ; Humans ; Hypertension ; prevention & control ; Inflammation ; prevention & control ; Lipids ; blood ; Mental Disorders ; therapy ; Neoplasms ; prevention & control ; Thrombosis ; prevention & control

ABNORMALITIES during pregnancy are regarded as pathological pregnancy. Early detection of anomalies is urgent to take measures as soon as possible to prevent serious pregnancy complications. Procoagulant-anticoagulant imbalance is often the pathological basis of many pathological pregnancy conditions, leading to a hypercoagulable state. We compared the thromboelastographic parameters between pathological pregnancy and normal pregnancy patients, evaluated the value of thromboelastography in early detecting pathological pregnancy and predicting postpartum hemorrhage.
Diabetes, Gestational ; blood ; Female ; Humans ; Postpartum Hemorrhage ; blood ; prevention & control ; Pre-Eclampsia ; blood ; Pregnancy ; Pregnancy Complications, Hematologic ; blood ; Thrombelastography ; methods ; Venous Thrombosis ; blood

Blood Vessels ; injuries ; Extremities ; blood supply ; injuries ; Humans ; Ligation ; Pulmonary Embolism ; etiology ; prevention & control ; Vascular Surgical Procedures ; methods ; Venous Thrombosis ; etiology ; prevention & control

OBJECTIVE: To evaluate and summarize the relevant evidence of anticoagulation and bleeding risk management in patients with extracorporeal membrane oxygenation (ECMO), and provide the evidence-based basis for the management of anticoagulation and bleeding during ECMO treatment. METHODS: According to the evidence "6S" pyramid model, all evidence on ECMO anticoagulation management and bleeding risk was searched in relevant databases, organizations and guideline websites at home and abroad. Evidence types included guidelines, expert consensus, systematic evaluation, Meta-analysis and original study. The search time limit was from May 31, 2012 to May 31, 2022. Two researchers with evidence-based research background conducted independent literature quality evaluation of the retrieved evidence, and the evidence that met the quality standards was extracted and summarized based on the opinions of industry experts. RESULTS: A total of 315 articles were retrieved, and 13 articles were included, including 3 guidelines, 6 expert consensus, and 4 Meta-analysis. A total of 27 best evidences were summarized from 7 aspects, including the selection of ECMO anticoagulation, anticoagulation in priming, anticoagulation in operation, anticoagulation monitoring, bleeding and treatment, thrombosis and treatment, and prevention and management of terminal limb ischemia. CONCLUSIONS This study provides evidence-based basis for bleeding prevention and anticoagulant management in ECMO patients. It is recommended to selectively apply the best evidence after evaluating the clinical environmental conditions of medical institutions, so as to improve the prognosis of ECMO patients.
Humans ; Extracorporeal Membrane Oxygenation/adverse effects* ; Blood Coagulation ; Hemorrhage/etiology* ; Anticoagulants/adverse effects* ; Thrombosis/prevention & control* ; Retrospective Studies

Plaque disruption and subsequent thrombotic occlusion is the primary mechanism by which atherosclerosis leads to acute coronary syndromes and ischemic stroke. Platelets are the key component of arterial thrombus formation in response to sudden fissuring or rupture of the atheromatous plaque. Low dose aspirin (100~300 mg/day) rapidly inhibits platelets through permanent inactivation of the key platelet enzyme, cyclooxygenase (COX). The efficacy and safety of aspirin have been extensively studied in several populations, ranging from healthy individuals to highrisk patients with acute myocardial infarction or ischemic stroke. It is well established that aspirin reduces the risk of serious vascular events (death, myocardial infarction, and stroke) by approximately 25% in patients with established vascular diseases. However, long-term therapy with aspirin approximately doubles the risk of major extracranial bleeding (mostly gastrointestinal bleeding) and also increases the risk of hemorrhagic stroke. In contrast to the clear benefit of aspirin in secondary prevention, its benefits in primary prevention are less clear. A meta-analysis of primary prevention trials in men demonstrated that aspirin reduces the risk of myocardial infarction by approximately 30% but has no effects on the risk of stroke. By contrast, the Women's Health Study showed that aspirin reduces the risk of stroke by 17% but has no effects on the risk of myocardial infarction. The reasons for this discrepancy remain unclear, requiring additional studies. Taken together, aspirin is recommended for primary prevention in healthy individuals with an annual risk of vascular events >1.5%. In conclusion, aspirin is recommended for secondary prevention in all patients, but its risk-benefit ratio should be carefully considered for primary prevention.
Acute Coronary Syndrome ; Aspirin* ; Atherosclerosis ; Blood Platelets ; Hemorrhage ; Humans ; Male ; Myocardial Infarction ; Primary Prevention ; Prostaglandin-Endoperoxide Synthases ; Rupture ; Secondary Prevention ; Stroke ; Thrombosis ; Vascular Diseases ; Women's Health

OBJECTIVETo investigate the immunoregulation effects of umbilical cord mesenchymal stem cells (UC-MSCs) on the rats with collagen II induced arthritis (CIA).

METHODSThe rats were first immunized by intradermal injection of chicken collagen type II emulsified with complete Freund's adjuvant (CFA) to monitor their swelling of foot, hair color and action state. After injected UC-MSC by caudal vein, the rats were scored with the arthritis index (AI) once a week. Then, the concentration of interleukin (IL-6), tumor necrosis factor-α (TNF-α) in serum and D-dimer (D-D), antithrombin-III (AT-III), thrombomodulin (TM) in plasma were detected by ELISA.

RESULTSObvious swellings of the feet were found in the experiment group compared with normal one. ELISA analysis showed that the concentrations of IL-6, TNF-α, D-D and TM in plasma of the experiment group as of (200.48 ± 15.04) ng/L, (450.25 ± 45.39) ng/L, (274.26 ± 67.93) ng/L and (9.18 ± 0.84) µg/L, respectively were higher than of(167.62 ± 0.97) ng/L, (371.44 ± 21.26) ng/L, (193.95 ± 8.22) ng/L and (6.30 ± 0.32) µg/L respectively in normal group (P < 0.05), but the concentration of AT-III \[(89.57 ± 6.40) ng/L\] was lower than normal group \[(112.82 ± 1.74) ng/L\] (P < 0.05). The levels of cytokines through the UC-MSCs treatment were significantly different from the model group (P < 0.05). After 9 weeks, these cytokines in the UC-MSCs group were mostly the same as the normal group.

CONCLUSIONThe thrombophilia status of the CIA rats was caused by immune injury. The UC-MSCs reduced the production of inflammatory cytokines and regulated and repaired the balance of coagulation and anticoagulation system of the body to cure the immune-related thrombophilia.

Animals ; Antithrombins ; blood ; Arthritis, Experimental ; immunology ; physiopathology ; prevention & control ; Female ; Fibrin Fibrinogen Degradation Products ; analysis ; Inflammation ; Interleukin-6 ; blood ; Mesenchymal Stem Cell Transplantation ; Rats ; Rats, Sprague-Dawley ; Thrombosis ; prevention & control ; Tumor Necrosis Factor-alpha ; blood ; Umbilical Cord ; cytology

OBJECTIVEThe effect of tranexamic acid (TA) on patients receiving total knee arthroplasty (TKA) has been reported in many small clinical trials. But single trials are not sufficient enough to clarify the effectiveness and safety of TA. So, we carried out a meta-analysis of randomized controlled trials to investigate the efficacy and safety of the intravenous use of TA in TKA.

METHODSLiteratures were retrieved in Cochrane Library, OVID, PubMed, EMBASE, CNKI and Wanfang Data. All the related literatures were checked by two independent investigators and only the high quality randomized controlled trials were enrolled. Relevant data were analyzed using RevMan 5.1 to compare the difference of blood loss, transfusion and complications between TA group and control group.

RESULTSThere were 353 related literatures and only 22 randomized controlled trials met the inclusion criteria. The use of TA in TKA significantly reduced total blood loss by a mean of 435.41 ml (95% CI 300.62-570.21, P less than 0.01), post-operative blood loss by a mean of 406.69 ml (95% CI 333.16-480.22, P less than 0.01). TA also significantly lowered the transfusion rate (risk difference 0.30, 95% CI 0.21-0.39, P less than 0.01) and transfusion volume (mean difference 0.95 unit, 95% CI 0.53-1.37, P less than 0.01). The risks between TA group and control group in developing deep vein thrombosis and pulmonary embolism were not statistically significant.

CONCLUSIONTA is beneficial for patients undergoing TKA, which can significantly reduce total blood loss, postoperative blood loss, transfusion rate, and transfusion volume. Meanwhile TA is recommended to reduce deep vein thrombosis and pulmonary embolism following TKA.

Antifibrinolytic Agents ; therapeutic use ; Arthroplasty, Replacement, Knee ; Blood Loss, Surgical ; prevention & control ; Blood Transfusion ; Humans ; Postoperative Hemorrhage ; prevention & control ; Pulmonary Embolism ; chemically induced ; Randomized Controlled Trials as Topic ; Tranexamic Acid ; adverse effects ; therapeutic use ; Venous Thrombosis ; chemically induced

OBJECTIVETo investigate the impact of hemocoagulase on coagulatory function and deep venous thrombosis after abdominal surgery.

METHODSFrom June 2008 to January 2009, 60 cases (gastric cancer 20 cases, colonic cancer 40 cases) undergoing gastrointestinal surgery at the Union Hospital of Fujian Medical University were randomized to the hemocoagulase group and the control group(n=30 in each group). Intravenous hemocoagulase at a daily dose of 2U was used on the same day and the next day postoperatively in the hemocoagulase group. D-dimer(D-D), tissue plasminogen activator(t-PA), plasminogen activator inhibitor-1(PAI-1), PT, APTT, TT, platelet count were measured before and after operation. Doppler ultrasound examination was carried out to exclude deep venous thrombosis on the 5th to 7th days after operation.

RESULTSSignificant increased D-D, t-PA, PAI-1, prolonged PT, APTT, shortened TT and lower platelet count after surgery were noticed as compared to the baseline in both groups(P<0.05, P<0.01). PT, APTT, D-D, t-PA, and PAI-1 significantly increased, and TT significantly shortened in the hemocoagulase group as compared to the control group after surgery(P<0.05, P<0.01). Deep venous thrombosis in the left lower limbs was noticed in 7 patients(23.3%) in the hemocoagulase group and 3 cases(10.0%) in the control group, however the difference was not statistically significant(P>0.05).

CONCLUSIONSHypercoagulable state usually appears after abdominal surgery and use of hemocoagulase may aggravate hypercoagulability and increase the incidence of deep venous thrombosis in lower limbs after abdominal surgery. Preventative use of hemocoagulase must be administered with caution.

Adult ; Aged ; Aged, 80 and over ; Batroxobin ; adverse effects ; therapeutic use ; Blood Coagulation ; drug effects ; Female ; Gastrointestinal Neoplasms ; blood ; surgery ; Hemostatics ; adverse effects ; therapeutic use ; Humans ; Male ; Middle Aged ; Postoperative Complications ; etiology ; prevention & control ; Venous Thrombosis ; etiology ; prevention & control

Stroke ranks as one of the leading causes of death and the most common cause of permanent disability in adults in Korea. Timely recognition and treatment is imperative to reduce stroke-related morbidity and mortality. Patients with acute ischemic stroke should be evaluated for intravenous thrombolysis with recombinant tissue-plasminogen activator (rt-PA); antiplatelet drugs can be administered to those who do not qualify for rt-PA therapy. Adequate hydration and correction of possible hypoxia are necessary, and hyperglycemia and fever should be treated aggressively. Blood pressure management should be individualized on the basis of stroke pathophysiology. It is important to prevent and manage complications of acute stroke, such as pneumonia, urinary tract infection, bed sore, deep vein thrombosis, and joint contracture. Meticulous evaluation of etiology of ischemic stroke can determine the most appropriate acute management and would guide the secondary prevention of stroke.
Adult ; Anoxia ; Blood Pressure ; Cause of Death ; Contracture ; Fever ; Humans ; Hyperglycemia ; Joints ; Korea ; Mortality ; Platelet Aggregation Inhibitors ; Pneumonia ; Pressure Ulcer ; Secondary Prevention ; Stroke* ; Urinary Tract Infections ; Venous Thrombosis

Expanded polytetrafluoroethylene(ePTFE) grafts 4mm long and 1mm in diameter were implanted into the iliac artery of 100-150g male rats using standard microvascular technique. Prior to clamp removal, the cremaster muscle was isolated as an island flap based on the iliac artery and observed using intravital fluorescence microscopy. Fields which contained a bifurcation of a first order arteriole(80-100 microns diameter) into second order arteriole(50-80 microns) were chosen for observation. Platelets were labeled in vivo with acridine red to visualize and quantify the aggregates. Images of microemboli were counted manually and the area was measured by computerized planimetry. Six control grafts were implanted with no further processing, six were irrigated with heparin, and six were coated with tridodecylmethylammonium chloride(TDMAC) and heparin. Most thrombi appeared within the first five minutes after implantation in all groups. The total number of emboli observed in the control group was 91 pr animal, in the heparin irrigation group it was 84, and in the TDMAC-heparin group it was 22. The total thrombus area observed per animal was 137,660 +/- 29,467 microns 2 in the control group, 79,040 +/- 10,893 microns 2 in the heparin irrigation group, and 17,498 +/- 6,059 microns 2 in the TDMAC-heparin group (p<.01 vs control or heparin irrigation group). With this results we could find that heparin irrigation and TDMAC-heparin coating appear to reduce the number, size, and total amount of microemboli generated by ePTFE graft implantation and apparent thromboresistant property of TDMAC-heparin coating may have widespread application in many clinical and research areas and this experimental model can be used for evaluation of other graft matrials.
Ammonium Compounds/pharmacology ; Animal ; Blood Vessel Prosthesis/*adverse effects ; Heparin/pharmacology ; Male ; Microcirculation/surgery ; Polytetrafluoroethylene/adverse effects ; Rats ; Thrombosis/*etiology/prevention & control